Singapore markets open in 2 hours 12 minutes

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.5700-0.2000 (-11.30%)
At close: 04:00PM EDT
1.5900 +0.02 (+1.27%)
After hours: 06:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7700
Open1.7800
Bid1.5700 x 2900
Ask1.5900 x 3000
Day's range1.5300 - 1.8500
52-week range1.1100 - 14.3800
Volume9,657,479
Avg. volume2,114,637
Market cap97.617M
Beta (5Y monthly)1.81
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

    DURHAM, N.C., June 27, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL) (the "Company"), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses payable by the Com

  • Business Wire

    Precision BioSciences Announces $50 Million Offering of Common Stock

    DURHAM, N.C., June 21, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately $50.0 million. The offering is expected to close on or about June 24, 2022, subject to customary closing conditions. All

  • Business Wire

    Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

    DURHAM, N.C., June 21, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the "Agreement"). As part of the Agreement, Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a ther